Universe Pharmaceuticals INC (NASDAQ:UPC) Sees Significant Growth in Short Interest

Universe Pharmaceuticals INC (NASDAQ:UPC) saw a significant growth in short interest during the month of August. As of August 14th, there was short interest totaling 35,401 shares, a growth of 454.7% from the July 30th total of 6,382 shares. Based on an average trading volume of 2,816,444 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.7% of the company’s shares are sold short.

Universe Pharmaceuticals Price Performance

Universe Pharmaceuticals stock traded up $0.07 during mid-day trading on Friday, reaching $5.11. 7,143 shares of the company were exchanged, compared to its average volume of 804,755. The business has a fifty day moving average of $5.04 and a 200 day moving average of $3.67. The company has a quick ratio of 3.90, a current ratio of 4.05 and a debt-to-equity ratio of 0.04. Universe Pharmaceuticals has a 12-month low of $2.00 and a 12-month high of $17.96.

Universe Pharmaceuticals (NASDAQ:UPC) last announced its quarterly earnings results on Wednesday, July 29th. The company reported ($1.38) earnings per share (EPS) for the quarter. The firm had revenue of $4.52 million during the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.